Skip to content

Author

L. Lanfrancone

We have 2 of 121 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cell-cycle control of chromatin creates a therapeutic window for epigenetic therapy in tumors

It is demonstrated that low-dose palbociclib — at concentrations well below those required for cytostatic arrest — extends G1 without halting proliferation and that extending G1 creates a therapeutic window for epigenetic drugs.

K. Hayatigolkhatmi, R. Valzelli, E. Ceccacci et al. · 0 citations
Open access Aug 2026

Nanoparticles-mediated dual drug administration boosts therapeutic efficacy in drug resistant melanoma.

A dual-drug delivery system co-loading trametinib, MEK inhibitor, and alisertib, Aurora A kinase inhibitor was developed, optimized to maintain a previously established synergistic ratio which effectively overcome acquired resistance to standard-of-care therapies and induce durable tumor regression.

Giulia Lovati, Pietro Milesi, Paolo Fossati et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.